Pfizer, Astellas’ Xtandi OK’d for second prostate cancer variant

The FDA approved Pfizer and Astellas Pharma's Xtandi, or enzalutamide, as a treatment for men with non-metastatic castration- -More- …
Read the full story: BIO SmartBrief